Clinical Trials Browser

INDUSTRY × Aromatase Inhibitors × Clear all

NCT07222267 2026-03-18

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Phase 1 Recruiting

Breast Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

779 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04188548 2025-06-04

EMBER

Phase 1 Active not recruiting

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT01160211 2025-03-07

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Phase 3 Completed

369 enrolled 19 charts

Breast Neoplasms

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT05012644 2024-10-08

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

197 enrolled 16 charts

Breast Neoplasms

NCT05361655 2024-06-07

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

2,888 enrolled 17 charts

Breast Neoplasms

NCT05043506 2024-03-27

EUCHARIS

Breast Neoplasms

NCT03462251 2023-01-19

RIBBIT

Phase 3 Completed

Breast Neoplasms

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

Phase 2 Terminated

66 enrolled 40 charts

Breast Neoplasms

NCT01491737 2020-10-28

PERTAIN

Phase 2 Completed

258 enrolled 18 charts

Breast Neoplasms

NCT01446159 2020-06-02

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Phase 2 Completed

188 enrolled 32 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02970682 2019-07-12

STEM

Phase 2 Completed

Breast Neoplasms

NCT00044291 2015-07-31

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Phase 3 Completed

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00784888 2012-03-15

TAMARA

Breast Neoplasms

NCT00097344 2007-08-23

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Phase 3 Terminated

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular